Inside the KLOW stack: what each drug did

The short version: why the four drugs stay separate

Researchers placed four peptide drugs in one vial and hoped their effects might fit together. Peptide means a short chain built from protein parts. That idea produced the klow stack, but the four drugs remain separate. A common vial holds 80 mg in all, with 50 mg from GHK-Cu. The other three drugs each take a 10 mg share. BPC-157 is a 15-amino-acid chain from stomach protein, or a row of protein parts. TB-500 comes from thymosin beta-4. KPV is cut from a hormone, which is a message the body sends. Your body clears the drugs at unequal rates. The FDA hasn't approved any of them for KLOW. Researchers also haven't tested the four-part mix as one product. This page shows you which drug produced each finding for your decision.

What the klow blend vial holds

A common klow blend vial holds 80 mg. GHK-Cu accounts for 50 mg and carries copper. BPC-157 accounts for 10 mg and comes from stomach protein. TB-500 accounts for 10 mg and comes from thymosin beta-4. KPV accounts for 10 mg and is cut from a hormone. The three smaller drugs are each 10 mg. BPC-157 is a 15-amino-acid chain, or a row of protein parts. KPV is the smallest of the four, while BPC-157 is the largest. GHK-Cu supplies the greatest weight. That fact doesn't prove that it does the most work. The vial amounts don't show equal effects, teamwork, or help for your sore knee.

What KPV changed in swollen gut tissue

KPV takes a 10 mg share of the common vial.

KPV is a short chain cut from a hormone, which is a message the body sends. KPV can calm swelling. Swollen gut cells make more of a small gate that pulls KPV inside. Once KPV entered, it blocked some of the body's calls for swelling ^[3]. The paper used the numbers 6 and 8 as labels for two of those calls. In a 2008 study, KPV calmed human immune cells and gut cells kept in dishes. It also made bowel swelling less severe in mice ^[3]. The result may sound useful if your gut hurts. Yet no person took KLOW in that study. Researchers still don't know whether you or anyone else would get the same result from the mix.

What GHK-Cu changed in skin and collagen

GHK-Cu takes 50 mg of the common vial.

GHK-Cu is also called Copper Tripeptide-1, a name meaning three protein building blocks joined together. This chain holds copper in a 1:1 bond, or one copper share for one chain. More people have been studied with skin use than with any other KLOW drug. A 2015 review found that creams helped loose skin, small lines, and wrinkle depth ^[4]. In cells, researchers used 1 to 10 nanomolar, which names a very small amount mixed into liquid. The cells changed how they used 31.2% of the genes that were checked. A gene is an instruction a cell follows, and the study counted changes of at least half ^[5]. That doesn't mean your skin improved or that a shot works.

Other studies found that copper-holding GHK parts led to new blood vessels ^[11]. Treated human blood-vessel cells grew 33.1% more than untreated cells in a dish ^[10]. The paper also named a growth message called FGF-2. That message tells blood-vessel cells to grow. GHK-Cu supplies copper to a body protein that ties collagen and elastin together. Elastin gives your skin its spring. This may help skin hold its shape, but whole-body use has no approval.

What BPC-157 changed in tendons and blood flow

BPC-157 takes 10 mg of the common vial.

Body Protection Compound 157 comes from a section of stomach protein. In animals and cells, BPC-157 made blood-vessel cells respond to a growth message ^[8]. One rat study cut through the Achilles tendon. Shots of 10 micrograms, 10 nanograms, or 10 picograms, with a picogram meaning one trillionth of a gram, helped the tendon heal by every check used ^[2]. In 2025, two people got BPC-157 by vein. They got 10–20 mg and had no bad events ^[6]. A study with only 2 people can't show that it works for your tendon. Other rat work tied BPC-157 to vessel growth as muscle and tendon healed ^[12]. It has no FDA approval. BPC-157 appears in FDA's record of withdrawn nominations, having previously been in Category 2. The withdrawal leaves the listed safety concerns in place and grants no approval or compounding permission. In rats, half was gone in under about 30 minutes.

What TB-500 may change as wounds close

TB-500 takes 10 mg of the common vial.

This drug is a brief section of thymosin beta-4, a 43-amino-acid body protein built from a row of protein parts. Most useful studies tested the full protein, not TB-500. In a 1999 rat study, new skin covered 42% more wound area at 4 days and 61% more at 7 days. Wounds pulled shut at least 11% more by day 7 ^[1]. The tissue also grew more small blood vessels. Other rodent work found that full thymosin beta-4 helped wounds, vessels, and hair roots ^[9]. TB-500 is the short drug, so you can't credit it with every full-protein result. The gap between the short drug and thymosin beta-4 also matters in tested sport. WADA lists TB-500 as banned. Thin human evidence leaves you and your doctor without a sound answer about benefit.

What changes in KLOW vs glow

KPV is the main change in KLOW vs glow. GLOW has GHK-Cu, BPC-157, and TB-500. It doesn't have KPV. Adding KPV gives KLOW its fourth drug. KPV entered swollen cells from the gut and immune system at about 160 micromolar, a measure of the KPV mixture's strength ^[3]. That lab figure can't set your dose, but the result explains the interest in KPV and swelling.

People using the blends for research say KLOW eased more aches or gut trouble. A study with a comparison group hasn't checked those stories, so they aren't trial findings. The claim only fits what KPV did alone. Neither blend has been tested as a mix. KLOW also differs from WOLVERINE, which uses other drugs. Neither KLOW nor GLOW contains a GLP-1 drug, the kind used for blood sugar and weight. You can prove that their contents differ, not that their results will differ for you.